Hodgkin Lymphoma News

Overcoming PD-1 Resistance in Relapsed/Refractory Hodgkin Lymphoma - CancerNetwork

Overcoming PD-1 Resistance in Relapsed/Refractory Hodgkin Lymphoma CancerNetwork

Baseline plasma-informed circulating tumor DNA analyses comparing multiplex digital PCR and NGS for longitudinal monitoring in Hodgkin lymphoma - Nature

Baseline plasma-informed circulating tumor DNA analyses comparing multiplex digital PCR and NGS for longitudinal monitoring in Hodgkin lymphoma Nature

Understanding the Origins of Hodgkin Lymphoma Cells Could Lead to Better Diagnostics - WCM Newsroom

Understanding the Origins of Hodgkin Lymphoma Cells Could Lead to Better Diagnostics WCM Newsroom

Post-Treatment Fertility in Hodgkin Lymphoma - Hematology Advisor

Post-Treatment Fertility in Hodgkin Lymphoma Hematology Advisor

Brown-Shuler to Undergo Treatment for Hodgkin Lymphoma - Clemson University Athletics

Brown-Shuler to Undergo Treatment for Hodgkin Lymphoma Clemson University Athletics

U.S. Supreme Court Blocks Roundup Lawsuits Over Non-Hodgkin’s Lymphoma Warnings - AboutLawsuits.com

U.S. Supreme Court Blocks Roundup Lawsuits Over Non-Hodgkin’s Lymphoma Warnings AboutLawsuits.com

Non-Hodgkin Lymphoma Treatment Market Size, Forecast, 2034 - Fortune Business Insights

Non-Hodgkin Lymphoma Treatment Market Size, Forecast, 2034 Fortune Business Insights

FDA Approves Nivolumab Plus AVD for Untreated Classical Hodgkin Lymphoma - OncLive

FDA Approves Nivolumab Plus AVD for Untreated Classical Hodgkin Lymphoma OncLive

New treatment combination offers excellent results for early-stage Hodgkin lymphoma with less chemotherapy - UT MD Anderson

New treatment combination offers excellent results for early-stage Hodgkin lymphoma with less chemotherapy UT MD Anderson

FDA Orphan Drug Status Awarded to EO2463 in Indolent Non-Hodgkin Lymphoma - Targeted Oncology

FDA Orphan Drug Status Awarded to EO2463 in Indolent Non-Hodgkin Lymphoma Targeted Oncology

Transcriptome sequencing of Hodgkin lymphoma Hodgkin and Reed-Sternberg cells reveals escape from NK cell recognition and an unfolded protein response | Blood Cancer Journal - Nature

Transcriptome sequencing of Hodgkin lymphoma Hodgkin and Reed-Sternberg cells reveals escape from NK cell recognition and an unfolded protein response | Blood Cancer Journal Nature

Pembrolizumab Combo Shows Efficacy in Pediatric High-Risk Hodgkin Lymphoma - CancerNetwork

Pembrolizumab Combo Shows Efficacy in Pediatric High-Risk Hodgkin Lymphoma CancerNetwork

BrECADD Improves PFS Vs Nivolumab/AVD in Advanced-Stage Hodgkin Lymphoma - CancerNetwork

BrECADD Improves PFS Vs Nivolumab/AVD in Advanced-Stage Hodgkin Lymphoma CancerNetwork

Nodular lymphocyte-predominant Hodgkin lymphoma controversy and insights: a global NLPHL one working group summit report | Leukemia - Nature

Nodular lymphocyte-predominant Hodgkin lymphoma controversy and insights: a global NLPHL one working group summit report | Leukemia Nature

Favezelimab Combo Boosts PFS vs Chemo in PD-1–Refractory Hodgkin Lymphoma - CancerNetwork

Favezelimab Combo Boosts PFS vs Chemo in PD-1–Refractory Hodgkin Lymphoma CancerNetwork

Genome-scale spatial mapping of the Hodgkin lymphoma microenvironment identifies tumor cell survival factors - Nature

Genome-scale spatial mapping of the Hodgkin lymphoma microenvironment identifies tumor cell survival factors Nature

Evaluation of incidence and outcomes of transformed nodular lymphocyte predominant Hodgkin Lymphoma in the United States: a population-based cohort study - Nature

Evaluation of incidence and outcomes of transformed nodular lymphocyte predominant Hodgkin Lymphoma in the United States: a population-based cohort study Nature

Outlining Common Drawbacks to Prior Standards for Hodgkin Lymphoma - CancerNetwork

Outlining Common Drawbacks to Prior Standards for Hodgkin Lymphoma CancerNetwork

AZD3470 Displays Clinical Activity in Pretreated Classic Hodgkin Lymphoma - CancerNetwork

AZD3470 Displays Clinical Activity in Pretreated Classic Hodgkin Lymphoma CancerNetwork

Nivolumab/AVD: A New Standard in Untreated Advanced Hodgkin Lymphoma - CancerNetwork

Nivolumab/AVD: A New Standard in Untreated Advanced Hodgkin Lymphoma CancerNetwork

Primary extranodal marginal zone non-hodgkin lymphoma of the prostate: a case report - Frontiers

Primary extranodal marginal zone non-hodgkin lymphoma of the prostate: a case report Frontiers

Richter transformation to classical Hodgkin lymphoma following recurrent disseminated histoplasmosis in chronic lymphocytic leukemia: a Case Report - Frontiers

Richter transformation to classical Hodgkin lymphoma following recurrent disseminated histoplasmosis in chronic lymphocytic leukemia: a Case Report Frontiers

Nivolumab Plus AVD Reduces Disease Progression Risk in Adolescents With Advanced Classical Hodgkin Lymphoma - The ASCO Post

Nivolumab Plus AVD Reduces Disease Progression Risk in Adolescents With Advanced Classical Hodgkin Lymphoma The ASCO Post

Non-Hodgkin lymphoma survivor thankful for clinical trial - UT MD Anderson

Non-Hodgkin lymphoma survivor thankful for clinical trial UT MD Anderson

Progress in the Treatment of Advanced-Stage Classical Hodgkin Lymphoma in the PET-Adapted Era - CancerNetwork

Progress in the Treatment of Advanced-Stage Classical Hodgkin Lymphoma in the PET-Adapted Era CancerNetwork

What does Bayer's US Supreme Court win mean for the thousands of Roundup lawsuits? - Reuters

What does Bayer's US Supreme Court win mean for the thousands of Roundup lawsuits? Reuters

Report: Counties that spray the most glyphosate have higher non-Hodgkin lymphoma rates - Iowa Capital Dispatch

Report: Counties that spray the most glyphosate have higher non-Hodgkin lymphoma rates Iowa Capital Dispatch

Advanced stage classical Hodgkin lymphoma patients with a positive interim-PET (PET-2) Deauville score 5 after 2 ABVD cycles: a pooled analysis of three multicenter trials - Nature

Advanced stage classical Hodgkin lymphoma patients with a positive interim-PET (PET-2) Deauville score 5 after 2 ABVD cycles: a pooled analysis of three multicenter trials Nature

Study reveals promising new therapy for non-Hodgkin lymphoma - Medical Xpress

Study reveals promising new therapy for non-Hodgkin lymphoma Medical Xpress

Nivolumab Outperforms Brentuximab Vedotin in PFS in Classic Hodgkin Lymphoma - Targeted Oncology

Nivolumab Outperforms Brentuximab Vedotin in PFS in Classic Hodgkin Lymphoma Targeted Oncology

Distinct cell state ecosystems for nodular lymphocyte-predominant Hodgkin lymphoma - Nature

Distinct cell state ecosystems for nodular lymphocyte-predominant Hodgkin lymphoma Nature

Targeting CAR-T cell exhaustion in non-Hodgkin lymphoma: mechanistic insights and emerging clinical strategies - Frontiers

Targeting CAR-T cell exhaustion in non-Hodgkin lymphoma: mechanistic insights and emerging clinical strategies Frontiers

Low-Dose Nivolumab Offers Novel Strategy for Hodgkin Lymphoma Treatment - Targeted Oncology

Low-Dose Nivolumab Offers Novel Strategy for Hodgkin Lymphoma Treatment Targeted Oncology

Nodular lymphocyte-predominant Hodgkin lymphoma: Leah's story - Roswell Park Comprehensive Cancer Center

Nodular lymphocyte-predominant Hodgkin lymphoma: Leah's story Roswell Park Comprehensive Cancer Center

Bayer scores landmark victory as Supreme Court overturns Roundup verdict - Fierce Pharma

Bayer scores landmark victory as Supreme Court overturns Roundup verdict Fierce Pharma

Syncytial Variant of Nodular Sclerosis Classical Hodgkin’s Lymphoma With Hemophagocytic Lymphohistiocytosis: A Rare and Under-Characterized Entity - Cureus

Syncytial Variant of Nodular Sclerosis Classical Hodgkin’s Lymphoma With Hemophagocytic Lymphohistiocytosis: A Rare and Under-Characterized Entity Cureus

New Phase 3 Clinical Trial Opens for Pediatric, Adult Hodgkin Lymphoma Patients - Roswell Park Comprehensive Cancer Center

New Phase 3 Clinical Trial Opens for Pediatric, Adult Hodgkin Lymphoma Patients Roswell Park Comprehensive Cancer Center